Patents Examined by Kristin A Vajda
  • Small molecule inducers of autophagy
    Patent number: 11591319
    Abstract: Small molecule disruptors of Beclin-1/Bc1-2 protein-protein interactions induce autophagy and hence are useful for treating a variety of indications where stimulation of autophagy is therapeutically useful, including cancer, infection immunity, neurodegeneration, longevity.
    Type: Grant
    Filed: April 5, 2022
    Date of Patent: February 28, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jef De Brabander, Qiren Liang, Beth Levine, Wei-Chung Chiang
  • Composition of lipoamino acids and alkanediols, process for the preparation thereof, and cosmetic or pharmaceutical composition resulting therefrom
    Patent number: 11590066
    Abstract: Disclosed are a new composition of lipoamino acids and alkanediols, a process for the preparation thereof, and a cosmetic or pharmaceutical composition resulting therefrom.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: February 28, 2023
    Assignee: SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES SEPPIC
    Inventors: Jérôme Guilbot, Georges Dacosta, Virginie Barthe
  • Highly active CSF1R inhibitor compound
    Patent number: 11591328
    Abstract: The present invention relates to a CSF1R inhibitor, and in particular to a highly active CSF1R inhibitor compound having the structure of formula (I). Said compound of the present invention has high inhibitory activity on CSF1R.
    Type: Grant
    Filed: May 24, 2019
    Date of Patent: February 28, 2023
    Assignee: XIAMEN BIOTIME BIOTECHNOLOGY CO., LTD.
    Inventors: Shifeng Liu, Zhiyong Yu, Wei Pang, Ji Wang, Peng Chen
  • 2-thioxothiazolidin-4-one derivatives active as transthyretin ligands and uses thereof
    Patent number: 11584727
    Abstract: Compounds are provided for stabilizing protein transthyretin (TTR) and inhibiting amyloid fibril formation, for example, transthyretin-mediated amyloid fibril formation, and for treating, preventing, or ameliorating one or more symptoms of amyloid diseases, for example, transthyretin-related amyloidosis (ATTR).
    Type: Grant
    Filed: August 18, 2021
    Date of Patent: February 21, 2023
    Assignee: BSIM Therapeutics, S.A.
    Inventors: Rui Manuel Pontes Meireles Ferreira de Brito, Carlos José Vieira Simões, Teresa Margarida Vasconcelos Dias de Pinho e Melo, Bruno Lourenço da Silva Victor, Zaida Catarina Lourenço de Almeida, Ana Lúcia Cabral Cardoso Lopes, Bruno Filipe Oliveira Nascimento
  • Acyl hydrazone linkers, methods and uses thereof
    Patent number: 11576981
    Abstract: The present application is directed to compounds of Formula (I)-(VIII): compositions comprising these compounds and their uses, for example as medicaments and/or diagnostics.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: February 14, 2023
    Assignee: ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR)
    Inventors: Rima Al-awar, Andrew Zhang, Ahmed Mamai
  • Nucleotide analogs
    Patent number: 11572377
    Abstract: Disclosed herein, inter alia, are acyclic nucleotide analogs and methods of using an acyclic nucleotide analog for treating and/or ameliorating a papillomavirus infection.
    Type: Grant
    Filed: April 21, 2021
    Date of Patent: February 7, 2023
    Assignee: The Regents of the University of California
    Inventors: Karl Y. Hostetler, James R. Beadle, Nadejda Valiaeva
  • Inhibiting mutant isocitrate dehydrogenase 1 (mIDH1)
    Patent number: 11566013
    Abstract: This disclosure relates to compositions and methods for inhibiting mutant IDH1, useful in treatment of mIDH1 cancers including AML, as well as mIDH1-positive solid tumors such as glioma.
    Type: Grant
    Filed: November 19, 2020
    Date of Patent: January 31, 2023
    Assignee: FORMA Therapeutics, Inc.
    Inventors: Jian Lin, George P. Luke, Madhu Mondal
  • Pharmaceutical combinations for treating cancer
    Patent number: 11559516
    Abstract: The present invention is directed to a combination comprising a proteasome inhibitor and a compound of formula I or a pharmaceutically acceptable salt thereof: to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: January 24, 2023
    Assignee: Purdue Pharmaceutical Products L.P.
    Inventors: Thomas Jorg Mehrling, Enrique Maria Ocio
  • Compounds inhibiting Nef-calnexin interaction
    Patent number: 11561217
    Abstract: The invention relates to compounds and methods for restoring or preserving cholesterol efflux in a cell infected with Human Immunodeficiency Virus (HIV) by preventing or decreasing an interaction between Negative Regulatory Factor (Nef) protein and Calnexin protein, and methods for screening for such compounds.
    Type: Grant
    Filed: August 24, 2021
    Date of Patent: January 24, 2023
    Assignee: THE GEORGE WASHINGTON UNIVERSITY
    Inventors: Alexei Adzhubei, Michael Bukrinsky, Ruth Hunegnaw
  • Phosphoramidate derivatives of 5-fluoro-2?-deoxyuridine for use in the treatment of cancer
    Patent number: 11559542
    Abstract: Phosphoramidate derivatives of 5-fluoro-2?-deoxyuridine are disclosed for use in the treatment of cancer, especially in the treatment of cancer where the patient shows resistance, for example, in a patient with cells with a lowered level of nucleoside transporter proteins and/or with nucleoside kinase-deficient cells and/or with Mycoplasma-infected cells and/or with cells with a raised level of thymidylate synthase.
    Type: Grant
    Filed: April 6, 2021
    Date of Patent: January 24, 2023
    Assignee: NuCana plc
    Inventors: Christopher McGuigan, Jan Balzarini, Magdalena Slusarczyk, Blanka Gonczy, Paola Murziani
  • Crystalline form of L-glufosinate ammonium salt and process for production thereof
    Patent number: 11555046
    Abstract: The present disclosure relates to a novel crystalline form of L-glufosinate ammonium salt and a process for preparation thereof. The present disclosure also provides compositions comprising said form and a method for the control of undesired plant growth using said compositions.
    Type: Grant
    Filed: February 23, 2022
    Date of Patent: January 17, 2023
    Assignee: UPL LTD
    Inventors: Prashant Vasant Kini, Chandrasekhar Dayal Mudaliar, Ashishkumar Ravindra Mishra, Santosh Ganpat Shelke
  • Near-infrared absorbing composition, optical structure, and camera module and electronic device comprising the same
    Patent number: 11555132
    Abstract: Disclosed are a near-infrared absorbing composition, an optical structure, and a camera module and an electronic device including the same. The near-infrared absorbing composition includes a copper complex represented by Chemical Formula 1. Definitions of Chemical Formula 1 are the same as described in the detailed description.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: January 17, 2023
    Assignee: Samsung Electronics Co., Ltd.
    Inventors: Yong Joo Lee, Mi Jeong Kim, Changki Kim, Hyung Jun Kim, Hye Ran Kim, Jong Hoon Won, Jae Jun Lee
  • Fused 1,4-oxazepines and related analogs as BET bromodomain inhibitors
    Patent number: 11548899
    Abstract: The present disclosure provides fused 1,4-oxazepines and related analogs represented by Formula (I) and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1, R2a, R2b, R3a, R3b, R4, R5, A, and Y are as defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a condition or disorder responsive to inhibition of BET bromodomains such as cancer.
    Type: Grant
    Filed: February 15, 2017
    Date of Patent: January 10, 2023
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Bing Zhou, Yang Hu, Chao-Yie Yang, Chong Qin
  • Pyrazole derivatives
    Patent number: 11548873
    Abstract: The present invention relates to nitro-vinyl-pyrazole compounds of formula (B) wherein ring A, RB2 and RB3 are as defined in claim 1, as well as the manufacture of such compounds and their subsequent use in the production of agrochemicals and/or pharmaceuticals.
    Type: Grant
    Filed: December 1, 2020
    Date of Patent: January 10, 2023
    Assignee: SYNGENTA CROP PROTECTION AG
    Inventors: James Alan Morris, Sally Elizabeth Russell, Sean Ng
  • Benzamide or benzamine compounds useful as anticancer agents for the treatment of human cancers
    Patent number: 11548894
    Abstract: The described invention provides small molecule anti-cancer compounds for treating tumors that respond to cholesterol biosynthesis inhibition. The compounds selectively inhibit the cholesterol biosynthetic pathway in tumor-derived cancer cells, but do not affect normally dividing cells.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: January 10, 2023
    Assignee: The Board of Regents of The University of Texas System
    Inventors: Jef DeBrabander, Luis Parada
  • Biodegradable compound, lipid particle, composition comprising lipid particle, and kit
    Patent number: 11548857
    Abstract: The present embodiment provides a compound represented by the formula (1): Q-CHR2??(1) (Q is a nitrogen-containing aliphatic group containing two or more tertiary nitrogens but no oxygen, and R is an aliphatic group containing a biodegradable group). From the compound in combination with other lipids such as a lipid capable of reducing aggregation, lipid particles can be formed. Further, the compound can be used for a pharmaceutical composition to deliver an activator into cells.
    Type: Grant
    Filed: March 9, 2020
    Date of Patent: January 10, 2023
    Assignee: KABUSHIKI KAISHA TOSHIBA
    Inventors: Mitsuko Ishihara, Eiichi Akahoshi, Katsuyuki Naito, Emi Nozaki, Saeko Saruwatari
  • Emetine auristatin compounds
    Patent number: 11548889
    Abstract: The present disclosure relates to Emetine Auristatin compounds, pharmaceutical compositions and kits comprising such compounds, and methods for using such compounds or pharmaceutical compositions.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: January 10, 2023
    Assignee: Arizona Board of Regents on behalf of Arizona State University
    Inventors: George R. Pettit, Noeleen Melody
  • Amine composition, amine compound, production method, and application thereof
    Patent number: 11548847
    Abstract: Provided are a novel amine composition and a novel amine compound. Also provided are a method for producing the amine composition and amine compound, and an epoxy resin curing agent, an epoxy resin composition, a cured product, a urethane prepolymer curing agent, a polyurethane urea resin composition, a polyamide varnish, and a polyamide, each obtained using the amine composition and amine compound. The amine composition contains a compound represented by Formula (1), wherein A is a cyclic alkylene group, and B is a group containing an aryl group or a heteroaryl group.
    Type: Grant
    Filed: February 21, 2020
    Date of Patent: January 10, 2023
    Assignee: MITSUBISHI GAS CHEMICAL COMPANY, INC.
    Inventor: Yuiga Asai
  • Pharmaceutical aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
    Patent number: 11541058
    Abstract: The present invention relates to a pharmaceutical aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea, or a pharmaceutically acceptable alkanesulphonate salt thereof, that is a clear solution. Such a formulation is particularly suitable for intravenous or parenteral administration to a patient.
    Type: Grant
    Filed: August 20, 2018
    Date of Patent: January 3, 2023
    Assignee: PFIZER INC.
    Inventors: James Joseph Hussey, Andrew Gilbert Bright
  • Oral formulations of metronidazole and methods of treating an infection using same
    Patent number: 11541035
    Abstract: The present disclosure provides oral pharmaceutical compositions comprising: 1) metronidazole or a pharmaceutically acceptable salt thereof; and magnesium aluminum silicate; or 2) metronidazole or a pharmaceutically acceptable salt thereof; magnesium aluminum silicate; and a flavoring agent. Methods of treating infection utilizing the oral pharmaceutical compositions are also provided.
    Type: Grant
    Filed: January 16, 2019
    Date of Patent: January 3, 2023
    Assignee: Appili Therapeutics Inc.
    Inventors: Bernard J. Guarino, Jr., Jamie L. Doran, Zorana Radovic, Kevin Sullivan